Trade Name: DEXAMETHASONE SODIUM PHOSPHATE

Following information is meant for : Wholesalers, Suppliers, Exporters, Doctors, CROs, Comparator Supplies, Hospitals, MOH Tender Supplies, Generic, Brand, Cooperate Sourcing, India, Institutional Buyers.

Manufacturer: Somerset Therapeutics, LLC

Presentation: INJECTION, SOLUTION, HUMAN PRESCRIPTION DRUG

Strength: 10 mg/mL

Storage and handling

DEXAMETHASONE SODIUM PHOSPHATE Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA]

Disclaimer:
  1. These products are NOT FOR SALE in US territories. We offer them for Exports outside of US Territories to Trade Professionals or patients with a valid prescription.
  2. Trademark shown are property of their respective owners and GNH India does not lay any claim on them.
  3. Read more
  • No data
  • Dexamethasone sodium phosphate injection, USP is a water-soluble inorganic ester of dexamethasone which produces a rapid response even when injected intramuscularly.
  • Dexamethasone Sodium Phosphate, CHFNaOP, has a molecular weight of 516.41 and chemically is Pregn-4-ene-3, 20-dione, 9-fluoro-11, 17-dihydroxy-16-methyl-21 (phosphonooxy)-, disodium salt, (11u03b2, 16u03b1).
  • It occurs as a white to practically white powder, is exceedingly hygroscopic, is soluble in water and its solutions have a pH between 7.5 and 9.5. It has the following structural formula:
  • Each mL of Dexamethasone Sodium Phosphate Injection, USP (Preserved) 10 mg/mL contains dexamethasone sodium phosphate, USP equivalent to 10 mg dexamethasone phosphate; 13.5 mg sodium citrate, dihydrate; 10 mg benzyl alcohol; and Water for Injection, q.s. pH adjusted with citric acid or sodium hydroxide, if necessary. pH: 7.0 to 8.5.
  • CLINICAL PHARMACOLOGY
  • Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.
  • Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.
  • Arrayn- A. Intravenous or intramuscular administration
  • When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows:
  • Arrayn- 1. Endocrine disorders.
  • Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).
  • Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used).
  • Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.
  • Congenital adrenal hyperplasia.
  • Nonsuppurative thyroiditis.
  • Hypercalcemia associated with cancer.
  • 2. n
  • As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
  • Post-traumatic osteoarthritis.
  • Synovitis of osteoarthritis.
  • Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
  • Acute and subacute bursitis.
  • Epicondylitis.
  • Acute nonspecific tenosynovitis.
  • Acute gouty arthritis.
  • Psoriatic arthritis.
  • Ankylosing spondylitis.
  • 3. n
  • Arrayn- During an exacerbation or as maintenance therapy in selected cases of:
  • Systemic lupus erythematosus.
  • Acute rheumatic carditis.
  • 4. n
  • Pemphigus.
  • Severe erythema multiforme (Stevens-Johnson Syndrome).
  • Exfoliative dermatitis.
  • Bullous dermatitis herpetiformis.
  • Severe seborrheic dermatitis.
  • Severe psoriasis.
  • Mycosis fungoides.
  • 5. u00a0
  • Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:
  • Bronchial asthma.
  • Contact dermatitis.
  • Atopic dermatitis.
  • Serum sickness.
  • Seasonal or perennial allergic rhinitis.
  • Drug hypersensitivity reactions.
  • Urticarial transfusion reactions.
  • Acute noninfectious laryngeal edema (epinephrine is the drug of first choice).
  • 6. u00a0
  • Severe acute and chronic allergic and inflammatory processes involving the eye, such as:
  • Herpes zoster ophthalmicus.
  • Iritis, iridocyclitis.
  • Chorioretinitis.
  • Diffuse posterior uveitis and choroiditis.
  • Optic neuritis.
  • Sympathetic ophthalmia.
  • Anterior segment inflammation.
  • Allergic conjunctivitis.
  • Allergic corneal marginal ulcers.
  • Keratitis.
  • 7. u00a0
  • To tide the patient over a critical period of the disease in:
  • Ulcerative colitis (systemic therapy).
  • Regional enteritis (systemic therapy).
  • 8. u00a0
  • Symptomatic Sarcoidosis.
  • Berylliosis.
  • Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculosis chemotherapy.
  • Loeffler's syndrome not manageable by other means.
  • Aspiration pneumonitis.
  • 9. u00a0
  • Acquired (autoimmune) hemolytic anemia.
  • Idiopathic thrombocytopenic purpura in adults (I.V. only; I.M. administration is contraindicated).
  • Secondary thrombocytopenia in adults.
  • Erythroblastopenia (RBC anemia).
  • Congenital (erythroid) hypoplastic anemia.
  • 10. u00a0
  • For palliative management of:
  • Leukemias and lymphomas in adults.
  • Acute leukemic of childhood.
  • 11. u00a0
  • To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
  • 12. u00a0
  • Acute exacerbations of multiple sclerosis.
  • 13. n
  • Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapy.
  • Trichinosis with neurologic or myocardial involvement.
  • Diagnostic testing of adrenocortical hyperfunction.
  • Cerebral edema of diverse etiologies in conjunction with adequate neurological evaluation and management.
  • Systemic fungal infections.
  • No data
  • Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.
  • There is an enhanced effect of corticosteroids in patients with hypothyroidism and in those with cirrhosis.
  • Corticosteroids should be used cautiously in patients with ocular herpes simplex for fear of corneal perforation.
  • The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction must be gradual.
  • Psychic derangements may appear when corticosteroids are used ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.
  • Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
  • Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection, also in diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, and myasthenia gravis.
  • Growth and development of infants and children on prolonged corticosteroid therapy should be carefully followed.
  • Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles and, if exposed, to obtain medical advice.
  • Intra-articular injection of a corticosteroid may produce systemic as well as local effects.
  • Appropriate examination of any joint fluid present is necessary to exclude a septic process.
  • A marked increase in pain accompanied by local swelling, further restriction of joint motion, fever, and malaise are suggestive of septic arthritis. If this complication occurs and the diagnosis of sepsis is confirmed, appropriate antimicrobial therapy should be instituted.
  • Local injection of a steroid into a previously infected joint is to be avoided. Corticosteroids should not be injected into unstable joints.
  • Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See Dosage and Administration Section).
  • Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.
  • Arrayn- Fluid and electrolyte disturbances:
  • Sodium retention
  • Fluid retention
  • Congestive heart failure in susceptible patients
  • Potassium loss
  • Hypokalemic alkalosis
  • Hypertension
  • Arrayn- Musculoskeletal:
  • Muscle weakness
  • Steroid myopathy
  • Loss of muscle mass
  • Osteoporosis
  • Vertebral compression fractures
  • Aseptic necrosis of femoral and humeral heads
  • Pathologic fracture of long bones
  • Arrayn- Gastrointestinal:
  • Peptic ulcer with possible subsequent perforation and hemorrhage
  • Pancreatitis
  • Abdominal distention
  • Ulcerative esophagitis
  • Arrayn- Dermatological:
  • Impaired wound healing
  • Thin fragile skin
  • Facial erythema
  • Increased sweating
  • May suppress reactions to skin tests
  • Petechiae and ecchymoses
  • Arrayn- Neurological:
  • Convulsions
  • Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment
  • Vertigo
  • Headache
  • Arrayn- Ophthalmic:
  • Posterior subcapsular cataracts
  • Increased intraocular pressure
  • Glaucoma
  • Arrayn- Endocrine:
  • Menstrual irregularities
  • Development of cushingoid state
  • Suppression of growth in children
  • Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness
  • Decreased carbohydrate tolerance
  • Manifestations of latent diabetes mellitus
  • Increased requirements for insulin or oral hypoglycemic agents in diabetics
  • Arrayn- Metabolic:
  • Negative nitrogen balance due to protein catabolism
  • Arrayn- Miscellaneous:
  • Hyperpigmentation or hypopigmentation
  • Subcutaneous and cutaneous atrophy
  • Sterile abscess
  • Postinjection flare, following intra-articular use
  • Charcot-like arthropathy
  • Itching, burning, tingling in the ano-genital region
  • Arrayn- A. Intravenous or intramuscular administration
  • The initial dosage of Dexamethasone sodium phosphate injection, USP may vary from 0.50 mg/day to 9.0 mg/day depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. Usually the parenteral dosage ranges are one-third to one-half the oral dose given every 12 hours. However, in certain overwhelming, acute, life-threatening situations, administration of dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.
  • For the treatment of unresponsive shock high pharmacologic doses of this product are currently recommended. Reported regimens range from 1 to 6 mg/kg of body weight as a single intravenous injection to 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists.
  • For the treatment of cerebral edema in adults an initial intravenous dose of 10 mg is recommended followed by 4 mg intramuscularly every six hours until maximum response has been noted. This regimen may be continued for several days postoperatively in patients requiring brain surgery. Oral dexamethasone, 1 to 3 mg t.i.d., should be given as soon as possible and dosage tapered off over a period of five to seven days. Nonoperative cases may require continuous therapy to remain free of symptoms of increased intracranial pressure. The smallest effective dose should be used in children, preferably orally. This may approximate 0.2 mg/kg/24 hours in divided doses.
  • In treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day or 4u20138 mg dexamethasone every other day for 1 month have been shown to be effective.
  • The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, Dexamethasone sodium phosphate injection, USP should be discontinued and the patient transferred to other appropriate therapy. It should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient.
  • After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this later situation it may be necessary to increase the dosage of Dexamethasone sodium phosphate injection, USP for a period of time consistent with the patient's condition. If after a long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
  • Frequency of injection usually ranges from once every 3 to 5 days to once every 2 to 3 weeks. Frequent intra-articular injection may cause damage to joint tissue.
  • Dexamethasone Sodium Phosphate Injection, USP (Preserved) 10 mg/mL is clear, colorless solution and is supplied as follows:
  • The vial stopper closure is not made with natural rubber latex.
  • Storage
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F) [see USP Controlled Room Temperature]. Protect from light.
  • Store container in carton until contents are used.
  • For Product Inquiry call 1-800-417-9175.
  • Manufactured by:u00a0
  • Wintac Limited
  • Bangalore 562 123
  • India.
  • Code. No.: KR/DRUGS/KTK/28/289/97
  • Manufactured for:
  • Somerset Therapeutics, LLC
  • Somerset, NJ 08873
  • ST-DEX22/P/00
  • Issued: 01/ 2019
  • Container label
  • Carton label

Ask for Quote

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler, Supplier, Exporters from India of DEXAMETHASONE SODIUM PHOSPHATE (DEXAMETHASONE SODIUM PHOSPHATE) which is also known as DEXAMETHASONE SODIUM PHOSPHATE and Manufactured by Somerset Therapeutics, LLC. It is available in strength of 10 mg/mL.

DEXAMETHASONE SODIUM PHOSPHATE (DEXAMETHASONE SODIUM PHOSPHATE) is supplied for Tenders, Emergency imports, Un - licensed, Specials, Orphan drug, Name patient line, RLD supplies, Reference listed drugs, Comparator Drug, Bio-Similar, Innovator samples, For Clinical trials. Click to know price.

Browse Our Services And Processes

Name Patient Supply

Name Patient Supply

Validated Cold Chain Shipment

Validated Cold Chain Shipment

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

Our Process - The Gnh Way

Our Process - The Gnh Way

Other Pharmaceutical Products

Daptomycin - Daptonex

Daptomycin - Daptonex

Liposomal Amphotericin - B for Injection IP (AmBisome)

Liposomal Amphotericin - B for Injection IP (AmBisome)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Melphalan Injection IP 50mg (Alkacel)

Melphalan Injection IP 50mg (Alkacel)

Monobenzone Cream USP 20% (Albaquin)

Monobenzone Cream USP 20% (Albaquin)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Are you an existing customer or a vendor of GNH India? Log in here to